EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Cladribine Tablets and Rebif® Data at AAN 2018

ROCKLAND, Mass., April 13, 2018 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced data for Cladribine Tablets, an investigational treatment for multiple sclerosis (MS), and Rebif® (interferon beta-1a) wi…